SEARCH

SEARCH BY CITATION

References

  • 1
    Hadziyannis SJ, Sevastianos V. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther 2013; 37: 491.
  • 2
    Hu C-C, Lin C-L, Kuo Y-L, et al. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric pataients with chronic hepatitis C. Aliment Pharmacol Ther 2013; 37: 8190.
  • 3
    Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106: 14855.
  • 4
    Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36(Suppl. 1): S4756.
  • 5
    Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 67580.
  • 6
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 7
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 120717.
  • 8
    Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 145775.
  • 9
    Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, Daclatasvir, and the nonstructural protein 3 protease inhibitor, Asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 5428.
  • 10
    Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 21624.